Neuromodulation Market

Furthermore, the US with USD 3.3 billion market in 2024, held a significant share in the global neuromodulation market. 

• Medtronic plc (Ireland) received FDA approval for expanded deep brain stimulation (DBS) labeling for dystonia treatment, shifting from Humanitarian Device Exemption to full effectiveness status backed by clinical evidence. (December 04, 2025)
• Boston Scientific Corporation (US) announced a definitive agreement to acquire Nalu Medical in October 2025 for ~$533 million upfront (on remaining equity), expanding its neuromodulation portfolio for chronic pain via peripheral nerve stimulation (PNS).​The Nalu Neurostimulation System, FDA-cleared in 2019, delivers targeted relief for peripheral nerve pain using a miniaturized, battery-free implantable pulse generator powered wirelessly and controlled via smartphone app.(October 17,2025)
• Saluda Medical Pty Ltd (Australia) received FDA approval for its EVA™ automated programming platform in spinal cord stimulation (SCS) in January 2025, compatible with all Evoke® System patients.​EVA automates nerve scanning and therapy optimization using evoked compound action potentials (ECAPs) biomarkers, reducing programming time to under 13 minutes and improving clinic efficiency. (February 05, 2025)

Drivers: Rising Neurological Disease Burden and Aging Population

The neuromodulation market is driven by the increasing prevalence of neurological and chronic pain disorders, combined with rapid global population aging. Epilepsy affects approximately 50 million people worldwide, while Parkinson’s disease impacted around 6.2 million individuals globally in 2020, with nearly 90,000 new cases diagnosed annually in the United States. Chronic pain conditions affect millions and significantly increase long-term healthcare demand. Additionally, the global population aged 65 years and above is expected to rise from nearly 10% today to about 16% by 2050, leading to higher incidence of age-related neurological disorders. Growing investments in neuroscience research by organizations such as the NIH and increasing clinical adoption of neuromodulation therapies, including deep brain stimulation and spinal cord stimulation, are further supporting market growth due to their superior clinical outcomes compared to pharmacological treatments.

Opportunities: Personalized and Intelligent Neuromodulation Technologies

Technological innovation is creating strong growth opportunities in the neuromodulation market. The development of closed-loop systems that adapt stimulation in real time based on patient-specific neural signals is improving treatment precision and therapeutic outcomes. Miniaturized, rechargeable implantable devices with remote monitoring and programming capabilities are enhancing patient convenience while reducing follow-up visits and long-term healthcare costs. The integration of artificial intelligence is enabling optimized treatment for complex conditions such as treatment-resistant depression, while non-invasive neuromodulation technologies, including transcranial magnetic stimulation, are expanding adoption among patients seeking alternatives to surgery. These advancements are extending applications across chronic pain, movement disorders, migraine, and psychiatric indications, supporting broader market penetration and global expansion.

Challenges: Wallet-Busting Costs, Endless Paperwork, and Insurance Maze

Despite strong clinical benefits, the neuromodulation market faces significant challenges related to cost, regulation, and reimbursement. Implantable neuromodulation devices involve high device and procedural costs, limiting access for uninsured and underinsured populations. Regulatory approval pathways are lengthy and capital-intensive, as these devices are classified as high-risk and require extensive clinical trials and long-term safety data. Reimbursement remains inconsistent across regions, with strict eligibility criteria and delayed payer acceptance for newer indications. Even where clinical evidence is established, such as deep brain stimulation for severe obsessive-compulsive disorder, insurance coverage remains limited. These barriers contribute to relatively low adoption rates, particularly for spinal cord stimulation, despite large eligible patient populations.

The neuromodulation market makes medical devices that help control nerve signals to treat tough conditions like chronic pain, Parkinson’s, and epilepsy. Valued at USD 6.1 billion in 2024, it’s set to grow to USD 10.3 billion by 2030 at a 9.2% CAGR.This boom comes from more people facing neurological issues, an aging world population, and better treatments like smaller implants that recharge wirelessly. Doctors love them for being less invasive and working better for patients.​New ideas include “closed-loop” systems that auto-adjust based on body signals, plus non-surgery options like TMS for wider use in depression and migraines.